NASDAQ:TECH Bio-Techne Q4 2026 Earnings Report $72.54 +0.02 (+0.02%) As of 09:59 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Bio-Techne EPS ResultsActual EPS$0.52Consensus EPS $0.52Beat/MissBeat by +$0.00One Year Ago EPS$0.53Bio-Techne Revenue ResultsActual Revenue$321.19 millionExpected Revenue$314.63 millionBeat/MissBeat by +$6.57 millionYoY Revenue Growth+1.30%Bio-Techne Announcement DetailsQuarterQ4 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time6:00AM ETUpcoming EarningsBio-Techne's Q1 2027 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Bio-Techne Earnings HeadlinesIs Bio-Techne Stock Outperforming the Nasdaq?September 24 at 4:51 AM | barchart.comBio-Techne Shareholders Approve Merck Acquisition AgreementSeptember 23 at 5:30 PM | tipranks.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 24 at 1:00 AM | Paradigm Press (Ad)3 reasons to sell TECH and 1 stock to buy insteadSeptember 23 at 2:06 PM | msn.comBio-Techne Shareholders Approve Takeover by Merck KGaASeptember 23 at 2:06 PM | finance.yahoo.comBio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, GermanySeptember 23 at 9:20 AM | prnewswire.comSee More Bio-Techne Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bio-Techne? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bio-Techne and other key companies, straight to your email. Email Address About Bio-TechneBio-Techne (NASDAQ:TECH)oration (NASDAQ:TECH) is a global life sciences company that develops and supplies research, diagnostic and bioprocessing products. Its portfolio includes proteins, antibodies, immunoassays, molecular biology reagents, cell and gene therapy tools, and instruments used by academic, pharmaceutical, biotechnology and diagnostic laboratories. The company operates through brands including R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics. Its products support applications such as protein analysis, spatial biology, single-cell research, biomarker discovery, drug development and the manufacture of cell and gene therapies. Bio-Techne also provides instruments and consumables designed to simplify laboratory workflows and improve the analysis of biological samples. Founded in 1976 as Research and Diagnostic Systems, the company later became Techne Corporation and adopted the Bio-Techne name in 2014. It serves customers worldwide through direct operations, distributors and international facilities, with products used across research, clinical and biopharmaceutical markets.View Bio-Techne ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
